<http://schema.org/description>
"...Biogen Inc. announced that it intends to spin off its hemophilia business as an independent, publicly traded company. The new company, which will be named Bioverativ, will focus on the discovery and development of therapies for the treatment of hemophilia and other blood disorders, with existing marketed products for the treatment of hemophilia A and B. This role will be a part of the Bioverativ spin-off that is expected to be finalized in the beginning of 2017.\n\nThe FP&amp;A Manager will be wholly..."^^<http://www.w3.org/2001/XMLSchema#string>
<https://tapwage.com/company/code42/fp-a/jobs>